Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Du, Mike
- dc.contributor.author Mayer, Miguel Ángel, 1960-
- dc.contributor.author Leis Machín, Angela 1974-
- dc.contributor.author Ramírez Anguita, Juan Manuel
- dc.contributor.author Tan, Eng Hooi
- dc.date.accessioned 2025-05-16T05:43:46Z
- dc.date.available 2025-05-16T05:43:46Z
- dc.date.issued 2024
- dc.description.abstract Objective: Multiple treatment options are recommended for Systemic Lupus Erythematosus (SLE) by clinical guidelines. This study aimed to explore SLE treatment patterns as there is limited real-world data of SLE medication utilisation, especially in childhood-onset SLE (cSLE). Methods: We conducted a longitudinal cohort study using five routinely collected healthcare databases from four European countries (United Kingdom, France, Germany, and Spain). We described the characteristics of adult and paediatric patients at time of SLE diagnosis. We calculated the percentage of patients commencing SLE treatments in the first month and year after diagnosis, reported number of prescriptions, starting dose, cumulative dose, and duration of each treatment, and characterised the line of therapy. Results: We characterised 11,255 patients with a first diagnosis of SLE and included 5718 in our medication utilisation analyses. The majority of adult SLE patients were female (range 80-88 %), with median age of 49 to 54 years at diagnosis. In the paediatric cohort (n = 378), 66-83 % of SLE patients were female, with median age of 12 to 16 years at diagnosis. Hydroxychloroquine and glucocorticoids were common first-line treatments in both adults and children, with second-line treatments including mycophenolate mofetil and methotrexate. Few cases of monoclonal antibody use were seen in either cohort. Initial glucocorticoid dosing in paediatric patients was often higher than in adults. Conclusion: Treatment choices for adult SLE patients across four European countries were in line with recent therapeutic consensus guidelines. High glucocorticoid prescriptions in paediatric patients suggests the need for steroid-sparing treatment alternatives and paediatric specific guidelines.
- dc.format.mimetype application/pdf
- dc.identifier.citation Du M, Dernie F, Català M, Delmestri A, Man WY, Brash JT, et al. Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries. Eur J Intern Med. 2024 Dec;130:106-17. DOI: 10.1016/j.ejim.2024.08.008
- dc.identifier.doi http://dx.doi.org/10.1016/j.ejim.2024.08.008
- dc.identifier.issn 0953-6205
- dc.identifier.uri http://hdl.handle.net/10230/70420
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Eur J Intern Med. 2024 Dec;130:106-17
- dc.rights © 2024 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Drug utilisation
- dc.subject.keyword Epidemiology
- dc.subject.keyword Lupus
- dc.subject.keyword Real world evidence
- dc.subject.keyword Systemic lupus erythematosus
- dc.title Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion